[Rabies and other lyssaviruses].

Uirusu

Laboratory of Zoonotic Diseases, Department of Veterinary Medicine, Faculty of Applied Biological Sciences, Gifu University, 1-1 Yanagido, Gifu,501-1193, Japan.

Published: December 2004

Since rabies has not been reported in Japan for nearly the past 50 years, it has been relegated to the status of a forgotten infectious disease in this country. However,in the neighboring Asian countries, Africa, America, the number fo rabies cases had not decrease but on the contrary, seen an increasing trend. In Russia and the former Soviet Union countries (CIS countries), the number of information. Between 30,000 approximately 20,000 fatal cases of rabies in both humans and animals had been reported yearly butit was thought that the number might run up to hundred of thousands.japan, Taiwan, UK, Australia and New Zealand are rabies-free countries and should be considered the exception rather than the norm. Due to the long Lull in which rabies has not occurred in Japan,people tend to forget that the disease can infect all mammals including humans, with a mortality rate of 100% after manifestation of debilitating nervous symptoms and that is one of the most dangerous zoonotic viral diseases on earth.

Download full-text PDF

Source
http://dx.doi.org/10.2222/jsv.54.213DOI Listing

Publication Analysis

Top Keywords

[rabies lyssaviruses]
4
rabies
4
lyssaviruses] rabies
4
rabies reported
4
reported japan
4
japan years
4
years relegated
4
relegated status
4
status forgotten
4
forgotten infectious
4

Similar Publications

Immunological findings of West Caucasian bat virus in an accidental host.

J Virol

January 2025

Laboratory for Emerging Viral Zoonoses, WOAH Reference Laboratory for Rabies, FAO and National Reference Centre for Rabies, Department for Research and Innovation, Istituto Zooprofilattico Sperimentale delle Venezie, Legnaro, Italy.

Unlabelled: The genus includes seventeen viral species able to cause rabies, an acute and almost invariably fatal encephalomyelitis of mammals. Rabies virus (RABV), which represents the type species of the genus, is a multi-host pathogen that over the years has undergone multiple events of host-switching, thus occupying several geographical and ecological niches. In contrast, non-RABV lyssaviruses are mainly confined within a single natural host with rare spillover events.

View Article and Find Full Text PDF

Typing Arctic and Africa-2 clades of rabies virus using clade-defining single nucleotide polymorphisms.

Arch Microbiol

January 2025

Department of Biochemistry, Division of Biological Sciences, Indian Institute of Science, Bangalore, India.

Rabies is a deadly neurotropic, zoonotic disease with a mortality rate of 100% after symptoms appear. Rabies virus (RABV) is the primary cause of rabies disease in humans, and it mainly spreads via dog bites in developing countries. Over the course of RABV evolution, multiple RABV variants, called clades, have emerged.

View Article and Find Full Text PDF

Rabies transmitted from vampires to cattle: An overview.

PLoS One

January 2025

Department of Fish and Wildlife Conservation, Virginia Tech, Blacksburg, VA, United States of America.

Rabies is a zoonotic infectious disease of global distribution that impacts human and animal health. In rural Latin America, rabies negatively impacts food security and the economy due to losses in livestock production. The common vampire bat, Desmodus rotundus, is the main reservoir and transmitter of rabies virus (RABV) to domestic animals in Latin America.

View Article and Find Full Text PDF

Despite global initiatives to eliminate dog-mediated human rabies by 2030, the Arabian Peninsula faces challenges due to insufficient data. This review addresses the current rabies situation and knowledge gaps in the region and proposes One Health interventions. Employing a mixed-method approach combining scoping and systematic review, the study commenced with a Delphi discussion to identify knowledge gaps and set objectives.

View Article and Find Full Text PDF

Self-replicating RNA (srRNA) technology, in comparison to mRNA vaccines, has shown dose-sparing by approximately 10-fold and more durable immune responses. However, no improvements are observed in the adverse events profile. Here, we develop an srRNA vaccine platform with optimized non-coding regions and demonstrate immunogenicity and safety in preclinical and clinical development.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!